

Board of Directors

Our nine-member Board of Directors and six-member Executive Leadership Team comprise broad and global management experience, comprehensive biotech expertise and in-depth knowledge of Novozymes' business. The members' competencies combine to ensure expert management of the company.



Jørgen Buhl Rasmussen

Born 1955. Chairman of the Board since 2017. Adjunct Professor at Copenhagen Business School. Member of the Audit Committee and chairman of the Nomination and Remuneration Committee. Member of the Board since 2011. Elected for one year at a time.

Board positions

Chairman:

F. Uhrenholt A/S

Member:

Smurfit Kappa Group
Human Practice Foundation
Advisory Board of Axcel

Special competencies

International business and management expertise, specifically within sales, marketing, branding and acquisitions, and financial and accounting expertise.



Agnete Raaschou-Nielsen

Born 1957. Vice Chairman of the Board since 2017. Member of the Audit Committee and of the Nomination and Remuneration Committee. Member of the Board since 2011. Elected for one year at a time.

Board positions

Chairman:

Arkil Holding A/S
Brdr. Hartmann A/S
Danske Invest, three other UCITS funds and two AIF funds

Member:

Aktieselskabet Schouw & Co.
Danske Invest Management A/S

Member of Audit Committee:

Aktieselskabet Schouw & Co.

Special competencies

Expertise within business development and acquisitions, macroeconomics and intellectual property rights, and financial and accounting expertise.



Lars Green*

Born 1967. Executive Vice President, Business Services and Compliance, Novo Nordisk A/S. Chairman of the Audit Committee. Member of the Board since 2014. Elected for one year at a time.

** This board member is not regarded as independent in the sense of the definition in the Danish Recommendations on Corporate Governance that apply to Danish listed companies.*

Special competencies

In-depth knowledge of the Novo Group's business, international experience from managing global biotechnology and biopharma companies, and financial and accounting expertise.



Kasim Kutay*

Born 1965. CEO, Novo Holdings A/S. Member of the Board since 2017. Elected for one year at a time.

Board positions

Member:

Novo Nordisk A/S
ConvaTec Plc

** This board member is not regarded as independent in the sense of the definition in the Danish Recommendations on Corporate Governance that apply to Danish listed companies.*

Special competencies

Broad experience within biotechnology, mergers and acquisitions, and financial and accounting expertise.



Kim Stratton

Born 1962. Head of International Commercial, Shire International GmbH. Member of the Nomination and Remuneration Committee. Member of the Board since 2017. Elected for one year at a time.

Board positions

Member:

European Federation of Pharmaceutical Industries and Associations (EFPIA)

Special competencies

Broad international commercial experience within sales and marketing, emerging markets, innovation pipeline management and sustainability.



Mathias Uhlén

Born 1954. Professor at the Royal Institute of Technology (Sweden) and at the Technical University of Denmark (DTU). Member of the Board since 2007. Elected for one year at a time.

Board positions

Chairman:

Atlas Antibodies AB
Antibodypedia AB
ScandiBio Therapeutics AB

Vice Chairman:

Affibody Medical AB

Member:

Bure Equity AB

Special competencies

Broad experience in research and biotechnology.



Lena Bech Holskov

Born 1967. Safety Adviser.
Employee representative.
Member of the Board since
2013. Elected for four years at
a time.



Anders Hentze Knudsen

Born 1959. Senior Operator.
Employee representative.
Member of the Board since
2013. Elected for four years at
a time.



Lars Bo K ppler

Born 1962. Technician.
Employee representative.
Member of the Board since
2010. Elected for four years at
a time.